BILLERICA, Mass .– (COMMERCIAL THREAD) – Quanterix Corporation (NASDAQ: QTRX), a company that digitizes biomarker analysis with the goal of advancing precision health science, today announced a webinar hosted by Kevin Hrusovsky, President and CEO of Quanterix leadership, with leading pathologist Dr. John Roback, MD, Ph.D., professor of pathology and laboratory medicine, executive vice president of clinical operations and medical director of Emory Medical Laboratories, to discuss Emory’s implementation of a comprehensive SARS-CoV-2 screening program for students, faculty and staff.
With the continued spread of SARS-CoV-2, in particular the highly contagious Delta variant of the virus, this webinar will help demonstrate how the ultra-sensitive and Simoa-activated detection of viral antigen works in non-collected samples. invasive, and will provide an opportunity for the community to learn from the experiences of Dr Roback and his colleagues.
The webinar will take place on Thursday, September 16, 2021 at 9 a.m. EDT. The discussion will be kicked off by Dr Hrusovsky, who will provide insight into how Dr Roback’s work – coupled with advances in COVID / neurological biomarkers – holds promise for advancing the field of preventive medicine and precision health. A question-and-answer discussion will follow the presentation.
To register for the webinar, visit https://www.quanterix.com/webinars/.
Quanterix is a company that digitizes biomarker analysis with the goal of advancing precision health science. The company’s digital health solution, Simoa, has the potential to change the way healthcare is delivered today by giving researchers the ability to take a close look at the continuum from health to disease. Quanterix’s technology is designed to enable much earlier detection of disease, better prognosis, and improved treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation, and infectious diseases. The company was established in 2007 and is located in Billerica, Massachusetts. For more information, please visit https://www.quanterix.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “plan”, “anticipate”, “estimate” “,” Intend “and similar expressions (as well as other words or expressions referring to future events, conditions or circumstances) are intended to identify forward-looking statements. The forward-looking statements contained in this press release are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the documents filed by Quanterix with the United States Securities and Exchange Commission, including “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.